AMPH vs PFE
AMPH: A vertically integrated specialty pharmaceutical company focused on complex injectable, inhalation, and intranasal drug delivery. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | AMPH | PFE | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $26.20 | $29.85 | |
| Market cap | $1.1B | $170.1B | |
| P/E as of 2026-10-21 | 15.50 | 39.28 | AMPH lower |
| PEG as of 2026-10-21, 3-year EPS CAGR to FY2025 | 2.94 | n/a | |
| Net margin FY2025, SEC XBRL | +13.6% | +12.4% | AMPH higher |
| Gross margin FY2025, SEC XBRL | +49.5% | n/a | |
| Operating margin FY2025, SEC XBRL | +19.5% | n/a | |
| ROE FY2025, SEC XBRL | +12.4% | +9.0% | AMPH higher |
| ROA FY2025, SEC XBRL | +6.0% | +3.7% | AMPH higher |
| Debt / equity | 0.80 | 0.74 | PFE lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -1.6% | -1.6% | Tie |
| Revenue CAGR (3y) SEC XBRL | +13.0% | -14.8% | AMPH higher |
| Dividend yield as of 2026-09-02 | n/a | +6.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 11 | PFE higher |
| Beta as of 2026-09-03 | 0.64 | 0.38 | |
| 1-year return as of 2026-10-21 close | +8.0% | +20.1% | PFE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.